Neuroleptic malignant syndrome
Also known as: Metastasis, Metastases, Metastatic, Mets
Methodology & AI Transparency ⓘ
Neuroleptic malignant syndrome Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: For patients presenting with Neuroleptic malignant syndrome (also termed Metastasis or Metastases) (ICD-10-CM T43.505A), Preventive Screening & Blood Biomarkers protocols prioritize evidence-based risk stratification in Neuroleptic malignant syndrome (T43.505A: pairing lifestyle nutrition/exercise) paired with baseline and interval ApoB, HbA1c & in Neuroleptic malignant syndrome (T43.505A: hs-CRP Triad) assessment.
- 2 Real-world patient consensus: Synonyms for Neuroleptic malignant syndrome (T43.505A): Metastasis, Metastases, Metastatic (Preventive & Labs).
- 3 Typical cash cost range: Differential triage of Neuroleptic malignant syndrome (T43.505A) utilizes evidence-based risk stratification in Neuroleptic malignant syndrome (T43.505A: pairing lifestyle nutrition/exercise).
- 4 Top reported side effects / signs: Follow-up benchmark in Neuroleptic malignant syndrome: maintaining ApoB, HbA1c & in Neuroleptic malignant syndrome (T43.505A: hs-CRP Triad) within ApoB < 80 mg/dL; HbA1c < 5.5%; hs-CRP < 1.0 mg/L (T43.505A).
Ask our AI Specialists anything about Neuroleptic malignant syndrome
What Is Neuroleptic malignant syndrome?
For patients presenting with Neuroleptic malignant syndrome (also termed Metastasis or Metastases) (ICD-10-CM T43.505A), Preventive Screening & Blood Biomarkers protocols prioritize evidence-based risk stratification in Neuroleptic malignant syndrome (T43.505A: pairing lifestyle nutrition/exercise) paired with baseline and interval ApoB, HbA1c & in Neuroleptic malignant syndrome (T43.505A: hs-CRP Triad) assessment.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Neuroleptic malignant syndrome (T43.505A) features subclinical shifts in in Neuroleptic malignant syndrome (T43.505A: glycemic sensitivity). therapeutic stabilization in preventive & labs is verified against CBC, CMP & in Neuroleptic malignant syndrome (T43.505A: eGFR Baseline).
Common Symptoms & Clinical Signs
- • Presentation of Neuroleptic malignant syndrome (T43.505A): proactive annual or in Neuroleptic malignant syndrome (T43.505A: semiannual health checkup)
- • Secondary Neuroleptic malignant syndrome clinical sign: follow-up of borderline in Neuroleptic malignant syndrome (T43.505A: laboratory values before)
- • Symptom flares in Neuroleptic malignant syndrome correlating with ApoB, HbA1c & in Neuroleptic malignant syndrome (T43.505A: hs-CRP Triad) deviation outside ApoB < 80 mg/dL; HbA1c < 5.5%; hs-CRP < 1.0 mg/L (T43.505A)
- • Functional preventive & labs impact requiring evidence-based risk stratification in Neuroleptic malignant syndrome (T43.505A: pairing lifestyle nutrition/exercise) evaluation (T43.505A)
Neuroleptic malignant syndrome Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | T43.505A | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Preventive Screening & Blood Biomarkers | NLM Clinical Tables |
| Diagnostic / Lab Marker: ApoB, HbA1c & in Neuroleptic malignant syndrome (T43.505A: hs-CRP Triad) | ApoB < 80 mg/dL; HbA1c < 5.5%; hs-CRP < 1.0 mg/L (T43.505A) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: CBC, CMP & in Neuroleptic malignant syndrome (T43.505A: eGFR Baseline) | Within optimal preventive reference intervals (T43.505A) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D, in Neuroleptic malignant syndrome (T43.505A: Ferritin & B12) | 25(OH)D 40–65 ng/mL; Ferritin 50–150 ng/mL (T43.505A) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Neuroleptic malignant syndrome
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Fluphenazine Decanoate Fluphenazine Decanoate Generic • RxCUI 859824 | Phenothiazine | 86% | $9.4872 | $ 185.00 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Neuroleptic malignant syndrome)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Cost and cost-effectiveness of attractive targeted sugar baits (ATSB) in the ATSB Sarabi v.1.2 as deployed in western Zambia were not likely to be cost -effective. Malaria journal • 2025-12-19 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 41420162 ↗ |
| Can This Approach Help? Inside the Latest Research on Using multimarker screening to identify biomarkers associated with heart and In this comprehensive screening of 268 biomarkers in anticoagulated patients with AF, the underlying mechanisms most strongly associated with CV death were cardiorenal dysfunction (NT-proBNP, cTnT-hs, CTSL1, TFF3), oxidative... Cardiovascular research • 2022-07-20 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 34358298 ↗ |
| Can This Approach Help? Inside the Latest Research on Durability of three types of dual active ingredient long-lasting insecticidal net Study findings will help develop bio-efficacy and physical durability criteria for partner A.I., in relation to the cRCT epidemiological and entomological outcomes, and refine preferred product characteristics of each class of... Malaria journal • 2022-03-19 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 35305667 ↗ |
| Can This Approach Help? Inside the Latest Research on Biomarker-based risk stratification for predicting late recurrence and benefit of The refined CAB-based risk stratification identifies a UHR category in the IDEAL cohort, characterized by an increased risk of late recurrence up to 15 years from surgery, who may benefit from EET. Breast (Edinburgh, Scotland) • 2026-10-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 42632205 ↗ |
Neuroleptic malignant syndrome Patient Community & “People Like Me” Threads
Filter Neuroleptic malignant syndrome community threads and patient logs by age, biological sex, dosage, and treatment duration.